Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.50 |
| ▸ | RARB | P10826 | 3/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11561346 | 1.00 | MEN1 (1.00) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL992112 | 1.00 | MEN1 (1.00) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL11558887 | 1.00 | MEN1 (1.00) | MEN1KMT2ATDP1TP53TSHR | |
| Tofa SCHEMBL543676 | 1.00 | MEN1 (1.00) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL13193431 | 1.00 | MEN1 (1.00) | MEN1KMT2ATDP1TP53TSHR | |
| Tofa SCHEMBL11555343 | 0.98 | MEN1 (0.97) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL8784383 | 0.98 | KMT2A (0.97) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL10669914 | 0.92 | TDP1 (0.84) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL10669926 | 0.92 | TDP1 (0.84) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL10423243 | 0.92 | TDP1 (0.84) | MEN1KMT2ATDP1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| WO-1996016535-A1 | METHOD OF PLANT TISSUE CULTURE | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1996-06-06 | — | — | WO | disclosed |
| US-4146623-A | SUBSTITUTED FUROIC ACIDS AND ESTERS | RICHARDSON-MERRELL INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4110351-A | Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts | RICHARDSON-MERRELL INC. (US) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | MEN1 4221/4885KMT2A 3171/4885TDP1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.